Tesamorelin
Tesamorelin is a growth hormone-releasing factor analog with a narrow FDA-approved prescription indication for reducing excess abdominal fat in a specific adult patient population with lipodystrophy.
Also known as: Egrifta SV, Egrifta WR
At a Glance
Tesamorelin is a growth hormone-releasing factor analog with a narrow FDA-approved prescription indication for reducing excess abdominal fat in a specific adult patient population with lipodystrophy.
Common Areas of Interest
Commonly discussed or studied in relation to:
Why People Are Interested
Because tesamorelin can affect visceral fat in its studied population, it is sometimes discussed more broadly in body-composition and longevity communities.
Evidence snapshot
Tesamorelin has meaningful human evidence for abdominal fat accumulation in one specific clinical population. That does not establish it as a general weight-loss or anti-aging treatment.
- Type of evidence
- Randomized controlled trials and FDA-reviewed clinical evidence
- Evidence level
- Established clinical evidence for a narrow approved indication
Evidence level describes the maturity and type of available research. It does not determine whether a treatment is appropriate for an individual.
Hype vs. Evidence
A calm way to separate popular online claims from what research currently supports.
What You May Hear
Tesamorelin is a proven peptide for losing belly fat or improving body composition.
What the Evidence Supports
Tesamorelin reduces visceral abdominal fat in the specific patient population it was studied and approved for.
What's Still Unknown
Its approved indication does not establish general weight-loss or anti-aging benefits for the broader population.
Regulatory / research status
Egrifta is approved to reduce excess abdominal fat in a specific adult patient population with lipodystrophy. FDA labeling specifically states that it is not indicated for weight-loss management.
Approval for one specific indication never implies approval or suitability for wellness, cosmetic, or anti-aging uses.
What We Know
Randomized trials demonstrated reductions in visceral adipose tissue in the specific clinical population studied.
What We Don't Know Yet
Those findings should not automatically be generalized to healthy-aging, cosmetic, or general weight-loss use.
Important Considerations
Keep the narrow approved indication prominent whenever discussing body-composition effects.
Questions for Your Healthcare Provider
- Is the use being discussed an FDA-approved use?
- How closely does the evidence population resemble the person considering it?
- What risks and monitoring requirements are relevant?
- Are there approved alternatives for the actual goal?
Sources
- EGRIFTA Prescribing Information
U.S. Food and Drug Administration · FDA labeling · Accessed August 31, 2026
- Randomized controlled trial of tesamorelin, a growth hormone-releasing factor, in patients with abdominal fat accumulation
Peer-reviewed clinical journal / PubMed · Randomized controlled trial · 2010 · PMID 20101189 · Accessed August 31, 2026
- Randomized controlled trial of tesamorelin's effect on visceral fat and liver fat in patients with abdominal fat accumulation
JAMA / PubMed · Randomized controlled trial · 2014 · PMID 25038357 · Accessed August 31, 2026
Last reviewed: August 31, 2026
Peptide Explorer provides general educational information only and is not medical advice. It does not diagnose, treat, prevent, or cure any condition and does not recommend specific peptides, medications, products, doses, or treatment protocols. Research and regulatory status may change over time. Always discuss health decisions with an appropriately qualified healthcare professional.